Mundasad MV, Novack GD, Allgood VE, Evans RM, Gorden JC, Yerxa BR. Ocular safety of INS365 ophthalmic solution: A P2Y2 agonist in healthy subjects. J Ocular Pharmacol Ther, 2001 Apr 17(2):173-179.
Yerxa BR, Mundasad M, Sylvester RN, Gorden JC, Cooper M, Kellerman DJ. Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease. Poster presented at the Third International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes: Basic Science and Clinical Relevance. 2000 November 15-18; Maui, Hawaii, USA.
Yerxa BR, Mundasad M, Sylvester RN, Garden JC, Cooper M, Kellerman DJ. Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease. Adv Exp Med Biol. 2002; 506(Pt B): 1251-1257
Foulks GN. Effects of diquafosol tetrasodium (a P2Y2 receptor agonist) on ocular surface staining. Presentation at EVER (European Association for Vision and Eye Research) 2003 Annual Meeting. 2003 October 8-11; Alicante, Spain. Powerpoint presentation in PDF
Foulks G, Sall K, Greenberg M, Tauber J, Donshik P, Berdy G, Sylvester R, Yerxa B, Crockett S, Kellerman D. Phase 2 dose ranging efficacy trial of INS365 ophthalmic solution, a P2Y2 agonist, in patients with dry eye. Powerpoint presentation by Gary Foulks, MD at the The Association for Research in Vision and Ophthalmology (ARVO) 2001 Annual Meeting. 2001 April 29 - May 4; Fort Lauderdale, Florida, USA.
Inspire Pharmaceuticals PROLACRIATM Program Background Information. 27 Jan 2009. Presentation in PDF
Brazzell R, Kellerman DJ, Schaberg A, Yerxa B,Durham T. Effect of diquafosol on ocular surface health in dry eye disease. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting. 2007 May 6-10; Fort Lauderdale, Florida, USA. Poster in PDF
Yerxa BJ, Brazzell RK, Kellerman DJ, Schaberg AE, Durham TA. Mechanism and Clinical Overview of Diquafosol Tetrasodium, a P2Y2 Agonist, For Dry Eye Disease. Powerpoint presentation by Dr. RK Brazzell at the XVII International Congress of Eye Research. 2006 October 29-November 3; Buenos Aires, Argentina. Abstract in PDF
Nichols KK, King-Smith PE, Nichols JJ, and Kellerman D. Tear film thickness and thinning rate following a six-week trial of 2% diquafosol tetrasodium vs. placebo in dry eye patients. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. 2006 April 30 - May 4; Fort Lauderdale, Florida, USA. Poster in PDF
Ousler III GW, Kellerman D, Durham T, Brazzell K, Kennedy K, Abelson MB. An association between central corneal staining and dry eye symptomatology. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. 2006 April 30 - May 4; Fort Lauderdale, Florida, USA. Poster in PDF
Schaberg AE, Durham TA, Kuhn KL, Caspar RA, LaVange LM. An evaluation of worst symptom reporting in a dry eye clinical trial. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2005 Annual Meeting. 2005 May 1-5; Fort Lauderdale, Florida, USA.
Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea, 2004 Nov;23(8):784-792.
Durham TA, LaVange LM, Kellerman DJ, Schaberg AE. Improvement in subject's worst symptom associated with treatment of 2.0% diquafosol tetrasodium in two studies of dry eye disease. Poster presentation at the 4th Annual International Conference on the Lacrimal Gland, Tear Film, Ocular Surface and Dry Eye Syndromes. 2004 November 17-20; Fajardo, Puerto Rico. Poster in PDF
Schaberg A, Ousler G, Kellerman D, LaVange L, Durham T, Yerxa B. Diquafosol tetrasodium (INS365) treatment and corneal clearing: Evidence from clinical trials. Poster presentation at the 4th Annual International Conference on the Lacrimal Gland, Tear Film, Ocular Surface and Dry Eye Syndromes. 2004 November 17-20; Fajardo, Puerto Rico. Poster in PDF
Barber LD, Durham T, LaVange L, Kellerman D, Schaberg A, Sall K, Nichols K, Yerxa B. Effect of diquafosol on worst symptom of dry eye patients: focus on photophobia. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting. 2004 April 25-29; Fort Lauderdale, Florida, USA. Poster in PDF
Kellerman DJ, Ousler G, Abelson M, Welch D, Mayhew A, Durham T, LaVange L, Yerxa B. Placebo-controlled evaluation of diquafosol in a controlled adverse environment (CAE). Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting. 2004 April 25-29; Fort Lauderdale, Florida, USA.
Sheppard J, Alison N, Martin D, Durham T, LaVange L, Kellerman D, Yerxa B,Schaberg A. Diquafosol tetrasodium is effective in a broad spectrum of patients with dry eye. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting. 2004 April 25-29; Fort Lauderdale, Florida, USA. Poster in PDF
Foulks GN. Effects of diquafosol tetrasodium (a P2Y2 receptor agonist) on ocular surface staining. Presentation at EVER (European Association for Vision and Eye Research) 2003 Annual Meeting. 2003 October 8-11; Alicante, Spain. Powerpoint presentation in PDF
Donshik P, Tauber J, Schaberg AE, Durham T, LaVange LM, Yerxa BR, Kellerman DJ. Diquafosol tetrasodium reduces corneal and conjunctival staining in subjects with dry eye, with the largest benefit relative to placebo observed in subjects with severe disease. Poster presented at the 23rd Biennial Cornea Research Conference. 2003 October 3-4; Boston, Massachusetts, USA. Poster in PDF
Kellerman DJ, Sall KN, Bokosky JE, Mills-Wilson MC, Whitsell RS, Kaufman BD, Yerxa BR. Diquafosol tetrasodium (INS365) ophthalmic solution is not absorbed systemically in patients with dry eye. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2003 Annual Meeting. 2003 May 4-9; Fort Lauderdale, Florida, USA. Poster in PDF
Denufosol tetrasodium inhalation solution for cystic fibrosis - Phase 3
(diquafosol tetrasodium ophthalmic solution) 2% for dry eye - Phase 3; Approvable
(azithromycin ophthalmic solution) 1% for blepharitis - Phase 2
INS115644 and INS117548 for glaucoma - Phase 1
© Inspire Pharmaceuticals 2010 All Rights Reserved
Terms of Use Legal Notices
Page Updated on: 5/17/2010
